Image

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.

Eligibility

For patient

Inclusion Criteria:

  • Adults (≥18 years) with NSCLC who have received osimertinib as the 3rd generation EGFR-TKI adjuvant therapy and meet one of the following: Patients who received adjuvant osimertinib for less than 34 months and discontinued treatment (off treatment), or Patients who received adjuvant osimertinib for at least 34 months (either off treatment or still on treatment).
  • For off treatment patients, discontinuation or completion of osimertinib is required to occur within 6 months by screening.
  • Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.

Exclusion Criteria:

  • Prior receipt of 3rd generation EGFR-TKI as adjuvant therapy as part of any interventional clinical trial.
  • Prior receipt of 1st generation EGFR-TKIs as adjuvant therapy.
  • Evidence of cognitive impairment that would likely to interfere with participation in an interview, as informally assessed during screening.
  • Unaware of or do not understand their own medical condition.

For physicians

Inclusion Criteria:

  • Licensed medical oncologists, thoracic surgeons, or pulmonologists with experience of prescribing osimertinib as adjuvant treatment and actively managing patients who will participate the interview.
  • Managed 5 patients with early-stage NSCLC receiving osimertinib within the past 6 months.
  • Holding a professional title equivalent to or higher than attending physician.
  • Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.

Exclusion Criteria:

  • Unable or unwilling to follow study procedures.

Study details
    Non-small Cell Lung Cancer

NCT07542210

AstraZeneca

5 September 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.